Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895122 | 0.87 | P2RX7 (0.44) | AAK1KMT2AHSD17B10POLBSMN1; SMN2 | |
| SCHEMBL4894721 | 0.82 | AAK1 (0.43) | AAK1KMT2APOLBLMNAL3MBTL1 | |
| SCHEMBL4890211 | 0.81 | SMN1; SMN2 (0.47) | KMT2AHSD17B10POLBLMNASMN1; SMN2 | |
| SCHEMBL14087734 | 0.77 | MEN1 (0.44) | AAK1KMT2APOLBLMNAL3MBTL1 | |
| SCHEMBL4890917 | 0.77 | KDM4E (0.41) | AAK1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL4884311 | 0.76 | KDM4E (0.48) | AAK1KMT2APOLBLMNAL3MBTL1 | |
| SCHEMBL4884281 | 0.76 | KDM4E (0.44) | AAK1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL4892789 | 0.75 | KDM4E (0.39) | AAK1KMT2AL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL14087809 | 0.75 | L3MBTL1 (0.43) | AAK1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL4744922 | 0.75 | L3MBTL1 (0.43) | AAK1KMT2ALMNAL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | AAK1 3977/4885KMT2A 2650/4885HSD17B10 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.